Absolute Eosinophil Count (AEC) Cutoffs for Eosinophilia
Blood eosinophilia is defined as AEC >0.5 × 10⁹/L (>500 cells/μL), hypereosinophilia as AEC ≥1.5 × 10⁹/L (≥1,500 cells/μL), and severe hypereosinophilia as AEC ≥5.0 × 10⁹/L, with specific disease thresholds varying by condition. 1, 2
Standard Eosinophilia Classification
The most recent UK guidelines (2025) establish the fundamental framework 1:
- Mild eosinophilia: 0.5-1.5 × 10⁹/L (500-1,500 cells/μL)
- Hypereosinophilia (HE): ≥1.5 × 10⁹/L (≥1,500 cells/μL) on two examinations at least 1 month apart
- Severe hypereosinophilia: ≥5.0 × 10⁹/L (≥5,000 cells/μL)
Critical threshold for urgent evaluation: Any patient with eosinophilia ≥1.5 × 10⁹/L persisting >3 months without identified cause requires hematology referral after excluding infectious etiologies 1. Immediate medical assessment is mandatory for any degree of eosinophilia with evidence of end-organ damage (cardiac, pulmonary, neurologic).
Disease-Specific Cutoffs
Hypereosinophilic Syndrome (HES)
The 2020 WHO/NCCN criteria define HES as 2:
- AEC ≥1.5 × 10⁹/L sustained for ≥6 months (or shorter if life-threatening)
- Evidence of eosinophil-mediated end-organ damage
- Exclusion of secondary causes
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
The 2023 Nature Reviews Rheumatology guidelines specify 3:
- Diagnostic threshold: >10% eosinophils OR >1,500 cells/μL
- 2022 ACR-EULAR classification: AEC ≥1.0 × 10⁹/L (+5 points in scoring system)
- Note: Glucocorticoid use can mask eosinophilia in EGPA patients
Allergic Bronchopulmonary Aspergillosis (ABPA)
The 2024 European Respiratory Journal guidelines recommend 4:
- Blood eosinophil cutoff: ≥500 cells/μL
- This threshold guides therapy decisions (anti-type 2 biologics, combination therapy)
- Sputum eosinophilia may be more accurate but is underutilized
Eosinophilic Asthma
Recent 2025 data demonstrates 5:
- Eosinophilic asthma threshold: ≥150 cells/μL
- Exacerbation severity shows U-shaped relationship: highest admission risk at <30 or >1,000 cells/μL
- Moderate elevation (150-300 cells/μL) associated with lowest admission risk
- AEC ≥300 cells/μL during exacerbation predicts shorter hospital stay
Tissue Eosinophilia Standards
Eosinophilic Esophagitis (EoE)
The 2022 British Society of Gastroenterology guidelines establish 6:
- Diagnostic threshold: >15 eosinophils per 0.3 mm² (equivalent to high-power field) in any biopsy
- Remission: <15 eosinophils per 0.3 mm²
- Requires 6 biopsies from ≥2 esophageal sites for 97-100% diagnostic sensitivity
- Must exclude GERD (typically <5 eosinophils/hpf)
Chronic Rhinosinusitis with Nasal Polyps
The 2020 European Position Paper defines 7:
- Eosinophilic CRS: 8-12 eosinophils per high-power field
- Severe eosinophilic CRS: >55 eosinophils/HPF (highest sensitivity/specificity for recurrence prediction)
- Stratification: 10-100 eosinophils/HPF vs >100 eosinophils/HPF in ≥2 areas
Clinical Decision Algorithm
For peripheral blood eosinophilia evaluation:
AEC 0.5-1.5 × 10⁹/L (mild): Consider allergic causes, medications, parasitic infection based on travel history. Repeat in 1 month if persistent.
AEC ≥1.5 × 10⁹/L (hypereosinophilia):
- Immediately assess for end-organ damage (cardiac enzymes, echocardiogram, pulmonary function, neurologic exam)
- If symptomatic or organ damage present: urgent hematology/cardiology consultation
- Exclude secondary causes (parasites, drugs, malignancy)
- If persistent >3 months without cause: hematology referral for clonal evaluation
AEC ≥5.0 × 10⁹/L (severe): Urgent evaluation for HES, clonal eosinophilia, or EGPA regardless of symptoms
Common pitfall: Do not attribute hypereosinophilia (≥1.5 × 10⁹/L) to allergy alone—this threshold always warrants comprehensive workup 8. Allergic conditions typically cause mild eosinophilia only.
Important caveat: Corticosteroid therapy rapidly suppresses eosinophil counts, potentially masking underlying disease severity. Obtain baseline AEC before initiating steroids when possible 3.